HIND Vyome Holdings, Inc.
Company Updates ·
The board appointed Jerry Leonard as chief financial officer on August 27, 2026, effective September 1, 2026, under a consulting agreement with ClearbridgeCFO, LLC, after interim CFO Robert Dickey gave notice of his resignation.
Vyome reported a net loss attributable to common shareholders of approximately $963,000 for the quarter ended March 31, 2026, and cash of approximately $8.8 million, while announcing an in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise.
ReShape says sales under its at-the-market program and a June 9 offering have lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The company says that does not guarantee it will stay listed.
Maxim Group LLC is the exclusive sales agent for up to $9,700,000 of stock, for a 3.0% commission. Two days earlier, Nasdaq had determined to delist ReShape, whose stockholders' equity was $1.2 million at March 31, 2025.
The company says it needs more time to compile its financial statements for the quarter ended March 31, 2025, including to reflect the May 9, 2025 reverse stock split.
ReShape says a reverse stock split on May 9, 2025 is one reason its March quarter 10-Q needs more time. It expects to file within the five-day extension and says it does not expect a significant change in results.
ReShape Lifesciences filed a Form NT 10-K on April 1, 2025, saying it needs more time to compile information for its 2024 annual report. The notice does not explain the delay, and the company's 2023 annual report set a cost reduction target of about 55.4% for 2024.
Vyome Holdings, Inc., formerly ReShape Lifesciences Inc., is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need. It completed a merger with Vyome Therapeutics, Inc. on August 15, 2025, and is based in Cambridge, MA, Princeton, NJ and New Delhi, India. Its lead program, VT-1953, is a topical gel being developed to treat signs and symptoms of malignant fungating wounds in advanced cancer. The company has announced positive results from a Phase 2 investigator-initiated trial and plans to hold discussions with the FDA on a pivotal Phase 3 trial design in the first half of 2026. VB1953, for moderate to severe acne, has completed its Phase II trial and is described as Phase 3-ready. VT-1908, an ophthalmic drops program for anterior uveitis, is at the pre-Investigational New Drug application stage. Its pharmaceutical segment has commercialized two topical antifungal products in India, a dandruff lotion and shampoo, sold under a licensing and marketing agreement with Sun Pharma Laboratories Limited. The company says it does not have any products approved for sale.
| Product or program | What it is | Stage |
|---|---|---|
| VT-1953 | Topical gel for signs and symptoms of malignant fungating wounds in advanced cancer | positive Phase 2 investigator-initiated trial results |
| VB1953 | Topical product for moderate to severe acne | Phase 3-ready |
| VT-1908 | Eye drop for anterior uveitis, steroid-sparing | pre-Investigational New Drug application stage |
| Antifungal dandruff lotion and shampoo | Reformulated topical antifungal products sold in India via Sun Pharma | commercialized in India |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $319,714 | $256,944 |
| Research and development | $588,258 | $285,391 |
| Net income (loss) | -$10.3 million | -$1.4 million |
| Cash from operations | -$3.7 million | -$614,136 |
| Cash and equivalents | $5.0 million | $101,904 |
Our latest story on this, dated May 15, 2025: "ReShape Lifesciences (now Vyome Holdings) files NT 10-Q, delaying its first-quarter 10-Q". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 30, 2025: "ReShape Lifesciences (now Vyome Holdings) sets up $9,700,000 at-the-market program". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 18, 2025: "ReShape Lifesciences (now Vyome Holdings) says equity tops Nasdaq $2.5 million minimum". The story links the filing or release it is based on. Read the story.
Vyome Holdings, Inc. trades under the ticker HIND on NASDAQ.
Vyome Holdings, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Vyome Holdings, Inc. is 1427570. Its filings are on SEC EDGAR.
7,018,528 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Vyome Holdings, Inc. under United States.
Our directory classifies Vyome Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Vyome Holdings, Inc. is US92943X1046.
aibio.space lists Vyome Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Vyome Holdings, Inc., formerly ReShape Lifesciences Inc., is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need. It completed a merger with Vyome Therapeutics, Inc. on August 15, 2025, and is based in Cambridge, MA, Princeton, NJ and New Delhi, India.
VT-1953: Topical gel for signs and symptoms of malignant fungating wounds in advanced cancer Stage: positive Phase 2 investigator-initiated trial results.
VB1953: Topical product for moderate to severe acne Stage: Phase 3-ready.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,4.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,3.03,5.02,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported an unregistered sale of its securities. SEC Form S-1. Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio